nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—SULT1E1—prostate cancer	0.612	1	CbGaD
Cyclizine—CYP2C9—Bicalutamide—prostate cancer	0.0469	0.294	CbGbCtD
Cyclizine—CYP2C9—Nilutamide—prostate cancer	0.0469	0.294	CbGbCtD
Cyclizine—CYP2C9—Estrone—prostate cancer	0.0281	0.176	CbGbCtD
Cyclizine—CYP2C9—Capecitabine—prostate cancer	0.0213	0.134	CbGbCtD
Cyclizine—CYP2C9—Estradiol—prostate cancer	0.0161	0.101	CbGbCtD
Cyclizine—SULT1E1—prostate gland—prostate cancer	0.00383	0.353	CbGeAlD
Cyclizine—CYP2C9—urine—prostate cancer	0.00193	0.178	CbGeAlD
Cyclizine—SULT1E1—testis—prostate cancer	0.00169	0.156	CbGeAlD
Cyclizine—SULT1E1—lymph node—prostate cancer	0.00122	0.113	CbGeAlD
Cyclizine—HRH1—prostate gland—prostate cancer	0.000685	0.0632	CbGeAlD
Cyclizine—HRH1—epithelium—prostate cancer	0.000503	0.0464	CbGeAlD
Cyclizine—HRH1—urethra—prostate cancer	0.000458	0.0423	CbGeAlD
Cyclizine—HRH1—testis—prostate cancer	0.000302	0.0278	CbGeAlD
Cyclizine—Bifonazole—CYP17A1—prostate cancer	0.000259	0.0992	CrCbGaD
Cyclizine—HRH1—lymph node—prostate cancer	0.000219	0.0202	CbGeAlD
Cyclizine—Nervous system disorder—Goserelin—prostate cancer	0.000171	0.00162	CcSEcCtD
Cyclizine—Mental disorder—Estradiol—prostate cancer	0.00017	0.00162	CcSEcCtD
Cyclizine—Tachycardia—Goserelin—prostate cancer	0.00017	0.00161	CcSEcCtD
Cyclizine—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000169	0.00161	CcSEcCtD
Cyclizine—Erythema—Estradiol—prostate cancer	0.000169	0.00161	CcSEcCtD
Cyclizine—Skin disorder—Goserelin—prostate cancer	0.000169	0.00161	CcSEcCtD
Cyclizine—Tachycardia—Conjugated Estrogens—prostate cancer	0.000168	0.0016	CcSEcCtD
Cyclizine—Urticaria—Ethinyl Estradiol—prostate cancer	0.000168	0.0016	CcSEcCtD
Cyclizine—Skin disorder—Conjugated Estrogens—prostate cancer	0.000168	0.00159	CcSEcCtD
Cyclizine—Injection site reaction—Epirubicin—prostate cancer	0.000167	0.00159	CcSEcCtD
Cyclizine—Urinary retention—Capecitabine—prostate cancer	0.000167	0.00158	CcSEcCtD
Cyclizine—Tension—Estradiol—prostate cancer	0.000166	0.00158	CcSEcCtD
Cyclizine—Dizziness—Bicalutamide—prostate cancer	0.000166	0.00157	CcSEcCtD
Cyclizine—Dyskinesia—Doxorubicin—prostate cancer	0.000166	0.00157	CcSEcCtD
Cyclizine—Nervousness—Estradiol—prostate cancer	0.000164	0.00156	CcSEcCtD
Cyclizine—Hypotension—Goserelin—prostate cancer	0.000163	0.00154	CcSEcCtD
Cyclizine—Muscle spasms—Estradiol—prostate cancer	0.000163	0.00154	CcSEcCtD
Cyclizine—Chills—Mitoxantrone—prostate cancer	0.000162	0.00154	CcSEcCtD
Cyclizine—Hypotension—Conjugated Estrogens—prostate cancer	0.000161	0.00153	CcSEcCtD
Cyclizine—Hepatobiliary disease—Etoposide—prostate cancer	0.000159	0.00151	CcSEcCtD
Cyclizine—Tremor—Estradiol—prostate cancer	0.000158	0.0015	CcSEcCtD
Cyclizine—Erythema—Mitoxantrone—prostate cancer	0.000158	0.0015	CcSEcCtD
Cyclizine—Insomnia—Goserelin—prostate cancer	0.000158	0.0015	CcSEcCtD
Cyclizine—Headache—Bicalutamide—prostate cancer	0.000157	0.00149	CcSEcCtD
Cyclizine—Agranulocytosis—Etoposide—prostate cancer	0.000157	0.00149	CcSEcCtD
Cyclizine—Paraesthesia—Goserelin—prostate cancer	0.000156	0.00148	CcSEcCtD
Cyclizine—Insomnia—Conjugated Estrogens—prostate cancer	0.000156	0.00148	CcSEcCtD
Cyclizine—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000156	0.00148	CcSEcCtD
Cyclizine—Agitation—Estradiol—prostate cancer	0.000155	0.00148	CcSEcCtD
Cyclizine—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000155	0.00147	CcSEcCtD
Cyclizine—Somnolence—Goserelin—prostate cancer	0.000155	0.00147	CcSEcCtD
Cyclizine—Injection site reaction—Doxorubicin—prostate cancer	0.000155	0.00147	CcSEcCtD
Cyclizine—Angioedema—Estradiol—prostate cancer	0.000155	0.00147	CcSEcCtD
Cyclizine—Bronchospasm—Docetaxel—prostate cancer	0.000154	0.00146	CcSEcCtD
Cyclizine—Somnolence—Conjugated Estrogens—prostate cancer	0.000153	0.00146	CcSEcCtD
Cyclizine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000152	0.00144	CcSEcCtD
Cyclizine—Pruritus—Ethinyl Estradiol—prostate cancer	0.00015	0.00142	CcSEcCtD
Cyclizine—Constipation—Goserelin—prostate cancer	0.000149	0.00141	CcSEcCtD
Cyclizine—Pain—Goserelin—prostate cancer	0.000149	0.00141	CcSEcCtD
Cyclizine—Bronchospasm—Capecitabine—prostate cancer	0.000149	0.00141	CcSEcCtD
Cyclizine—Vision blurred—Mitoxantrone—prostate cancer	0.000149	0.00141	CcSEcCtD
Cyclizine—Constipation—Conjugated Estrogens—prostate cancer	0.000148	0.0014	CcSEcCtD
Cyclizine—Pain—Conjugated Estrogens—prostate cancer	0.000148	0.0014	CcSEcCtD
Cyclizine—Hypertension—Estradiol—prostate cancer	0.000146	0.00139	CcSEcCtD
Cyclizine—Thrombophlebitis—Epirubicin—prostate cancer	0.000141	0.00134	CcSEcCtD
Cyclizine—Eye disorder—Etoposide—prostate cancer	0.000141	0.00134	CcSEcCtD
Cyclizine—Dizziness—Ethinyl Estradiol—prostate cancer	0.00014	0.00133	CcSEcCtD
Cyclizine—Hepatic function abnormal—Epirubicin—prostate cancer	0.00014	0.00133	CcSEcCtD
Cyclizine—Urticaria—Goserelin—prostate cancer	0.000138	0.00131	CcSEcCtD
Cyclizine—Anaphylactic shock—Estradiol—prostate cancer	0.000138	0.00131	CcSEcCtD
Cyclizine—Urticaria—Conjugated Estrogens—prostate cancer	0.000137	0.0013	CcSEcCtD
Cyclizine—Convulsion—Mitoxantrone—prostate cancer	0.000137	0.0013	CcSEcCtD
Cyclizine—Hypertension—Mitoxantrone—prostate cancer	0.000136	0.00129	CcSEcCtD
Cyclizine—Nervous system disorder—Estradiol—prostate cancer	0.000135	0.00129	CcSEcCtD
Cyclizine—Chills—Etoposide—prostate cancer	0.000135	0.00128	CcSEcCtD
Cyclizine—Tachycardia—Estradiol—prostate cancer	0.000135	0.00128	CcSEcCtD
Cyclizine—Phenoxybenzamine—SLC22A3—prostate cancer	0.000135	0.0515	CrCbGaD
Cyclizine—Skin disorder—Estradiol—prostate cancer	0.000134	0.00127	CcSEcCtD
Cyclizine—Headache—Ethinyl Estradiol—prostate cancer	0.000133	0.00126	CcSEcCtD
Cyclizine—Hepatobiliary disease—Docetaxel—prostate cancer	0.000132	0.00125	CcSEcCtD
Cyclizine—Bifonazole—CYP19A1—prostate cancer	0.000132	0.0505	CrCbGaD
Cyclizine—Thrombophlebitis—Doxorubicin—prostate cancer	0.00013	0.00124	CcSEcCtD
Cyclizine—Agranulocytosis—Docetaxel—prostate cancer	0.00013	0.00124	CcSEcCtD
Cyclizine—Hepatic function abnormal—Doxorubicin—prostate cancer	0.000129	0.00123	CcSEcCtD
Cyclizine—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000129	0.00122	CcSEcCtD
Cyclizine—Hypersensitivity—Goserelin—prostate cancer	0.000128	0.00122	CcSEcCtD
Cyclizine—Dermatitis bullous—Epirubicin—prostate cancer	0.000128	0.00121	CcSEcCtD
Cyclizine—Hepatobiliary disease—Capecitabine—prostate cancer	0.000128	0.00121	CcSEcCtD
Cyclizine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000127	0.00121	CcSEcCtD
Cyclizine—Muscle spasms—Etoposide—prostate cancer	0.000126	0.0012	CcSEcCtD
Cyclizine—Agranulocytosis—Capecitabine—prostate cancer	0.000126	0.0012	CcSEcCtD
Cyclizine—Tachycardia—Mitoxantrone—prostate cancer	0.000126	0.00119	CcSEcCtD
Cyclizine—Hepatitis—Docetaxel—prostate cancer	0.000125	0.00119	CcSEcCtD
Cyclizine—Asthenia—Goserelin—prostate cancer	0.000125	0.00119	CcSEcCtD
Cyclizine—Skin disorder—Mitoxantrone—prostate cancer	0.000125	0.00119	CcSEcCtD
Cyclizine—Insomnia—Estradiol—prostate cancer	0.000125	0.00119	CcSEcCtD
Cyclizine—Paraesthesia—Estradiol—prostate cancer	0.000124	0.00118	CcSEcCtD
Cyclizine—Asthenia—Conjugated Estrogens—prostate cancer	0.000124	0.00117	CcSEcCtD
Cyclizine—Pruritus—Goserelin—prostate cancer	0.000123	0.00117	CcSEcCtD
Cyclizine—Connective tissue disorder—Docetaxel—prostate cancer	0.000123	0.00117	CcSEcCtD
Cyclizine—Somnolence—Estradiol—prostate cancer	0.000123	0.00117	CcSEcCtD
Cyclizine—Pruritus—Conjugated Estrogens—prostate cancer	0.000122	0.00116	CcSEcCtD
Cyclizine—Hepatitis—Capecitabine—prostate cancer	0.000121	0.00115	CcSEcCtD
Cyclizine—Hypotension—Mitoxantrone—prostate cancer	0.00012	0.00114	CcSEcCtD
Cyclizine—Connective tissue disorder—Capecitabine—prostate cancer	0.000119	0.00113	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—prostate cancer	0.000118	0.00112	CcSEcCtD
Cyclizine—Pain—Estradiol—prostate cancer	0.000118	0.00112	CcSEcCtD
Cyclizine—Constipation—Estradiol—prostate cancer	0.000118	0.00112	CcSEcCtD
Cyclizine—Eye disorder—Docetaxel—prostate cancer	0.000117	0.00111	CcSEcCtD
Cyclizine—Paraesthesia—Mitoxantrone—prostate cancer	0.000116	0.0011	CcSEcCtD
Cyclizine—Dizziness—Goserelin—prostate cancer	0.000115	0.00109	CcSEcCtD
Cyclizine—Somnolence—Mitoxantrone—prostate cancer	0.000114	0.00109	CcSEcCtD
Cyclizine—Dizziness—Conjugated Estrogens—prostate cancer	0.000114	0.00108	CcSEcCtD
Cyclizine—Convulsion—Etoposide—prostate cancer	0.000114	0.00108	CcSEcCtD
Cyclizine—Eye disorder—Capecitabine—prostate cancer	0.000113	0.00108	CcSEcCtD
Cyclizine—Hypertension—Etoposide—prostate cancer	0.000113	0.00107	CcSEcCtD
Cyclizine—Chills—Docetaxel—prostate cancer	0.000112	0.00107	CcSEcCtD
Cyclizine—Flunarizine—CYP2A6—prostate cancer	0.000111	0.0426	CrCbGaD
Cyclizine—Constipation—Mitoxantrone—prostate cancer	0.00011	0.00104	CcSEcCtD
Cyclizine—Pain—Mitoxantrone—prostate cancer	0.00011	0.00104	CcSEcCtD
Cyclizine—Urticaria—Estradiol—prostate cancer	0.00011	0.00104	CcSEcCtD
Cyclizine—Mental disorder—Docetaxel—prostate cancer	0.00011	0.00104	CcSEcCtD
Cyclizine—Headache—Goserelin—prostate cancer	0.000109	0.00104	CcSEcCtD
Cyclizine—Erythema—Docetaxel—prostate cancer	0.000109	0.00103	CcSEcCtD
Cyclizine—Chills—Capecitabine—prostate cancer	0.000109	0.00103	CcSEcCtD
Cyclizine—Headache—Conjugated Estrogens—prostate cancer	0.000108	0.00103	CcSEcCtD
Cyclizine—Anaphylactic shock—Etoposide—prostate cancer	0.000107	0.00102	CcSEcCtD
Cyclizine—Mental disorder—Capecitabine—prostate cancer	0.000106	0.00101	CcSEcCtD
Cyclizine—Connective tissue disorder—Prednisone—prostate cancer	0.000106	0.00101	CcSEcCtD
Cyclizine—Erythema—Capecitabine—prostate cancer	0.000105	0.001	CcSEcCtD
Cyclizine—Muscle spasms—Docetaxel—prostate cancer	0.000105	0.000994	CcSEcCtD
Cyclizine—Tachycardia—Etoposide—prostate cancer	0.000104	0.000991	CcSEcCtD
Cyclizine—Skin disorder—Etoposide—prostate cancer	0.000104	0.000987	CcSEcCtD
Cyclizine—Urticaria—Mitoxantrone—prostate cancer	0.000102	0.00097	CcSEcCtD
Cyclizine—Hypersensitivity—Estradiol—prostate cancer	0.000102	0.000966	CcSEcCtD
Cyclizine—Muscle spasms—Capecitabine—prostate cancer	0.000101	0.000963	CcSEcCtD
Cyclizine—Eye disorder—Prednisone—prostate cancer	0.000101	0.000958	CcSEcCtD
Cyclizine—Hypotension—Etoposide—prostate cancer	0.0001	0.000949	CcSEcCtD
Cyclizine—Vision blurred—Capecitabine—prostate cancer	9.94e-05	0.000944	CcSEcCtD
Cyclizine—Diphenhydramine—CYP2C18—prostate cancer	9.91e-05	0.0379	CrCbGaD
Cyclizine—Asthenia—Estradiol—prostate cancer	9.9e-05	0.00094	CcSEcCtD
Cyclizine—Tremor—Capecitabine—prostate cancer	9.88e-05	0.000938	CcSEcCtD
Cyclizine—Bifonazole—CYP2E1—prostate cancer	9.83e-05	0.0376	CrCbGaD
Cyclizine—Pruritus—Estradiol—prostate cancer	9.77e-05	0.000927	CcSEcCtD
Cyclizine—Bifonazole—CYP2C19—prostate cancer	9.73e-05	0.0373	CrCbGaD
Cyclizine—Phenoxybenzamine—SLC22A1—prostate cancer	9.65e-05	0.0369	CrCbGaD
Cyclizine—Paraesthesia—Etoposide—prostate cancer	9.61e-05	0.000912	CcSEcCtD
Cyclizine—Somnolence—Etoposide—prostate cancer	9.51e-05	0.000903	CcSEcCtD
Cyclizine—Hypersensitivity—Mitoxantrone—prostate cancer	9.48e-05	0.0009	CcSEcCtD
Cyclizine—Mental disorder—Prednisone—prostate cancer	9.46e-05	0.000898	CcSEcCtD
Cyclizine—Convulsion—Docetaxel—prostate cancer	9.44e-05	0.000896	CcSEcCtD
Cyclizine—Hypertension—Docetaxel—prostate cancer	9.41e-05	0.000893	CcSEcCtD
Cyclizine—Drowsiness—Epirubicin—prostate cancer	9.4e-05	0.000893	CcSEcCtD
Cyclizine—Modafinil—CYP3A5—prostate cancer	9.4e-05	0.036	CrCbGaD
Cyclizine—Erythema—Prednisone—prostate cancer	9.4e-05	0.000892	CcSEcCtD
Cyclizine—Asthenia—Mitoxantrone—prostate cancer	9.23e-05	0.000876	CcSEcCtD
Cyclizine—Fentanyl—CYP3A5—prostate cancer	9.19e-05	0.0352	CrCbGaD
Cyclizine—Pain—Etoposide—prostate cancer	9.15e-05	0.000869	CcSEcCtD
Cyclizine—Constipation—Etoposide—prostate cancer	9.15e-05	0.000869	CcSEcCtD
Cyclizine—Dizziness—Estradiol—prostate cancer	9.13e-05	0.000867	CcSEcCtD
Cyclizine—Hypertension—Capecitabine—prostate cancer	9.11e-05	0.000865	CcSEcCtD
Cyclizine—Hepatobiliary disease—Epirubicin—prostate cancer	8.89e-05	0.000844	CcSEcCtD
Cyclizine—Anaphylactic shock—Docetaxel—prostate cancer	8.89e-05	0.000844	CcSEcCtD
Cyclizine—Vision blurred—Prednisone—prostate cancer	8.86e-05	0.000841	CcSEcCtD
Cyclizine—Cinnarizine—CYP2A6—prostate cancer	8.8e-05	0.0337	CrCbGaD
Cyclizine—Agranulocytosis—Epirubicin—prostate cancer	8.78e-05	0.000833	CcSEcCtD
Cyclizine—Nervous system disorder—Docetaxel—prostate cancer	8.72e-05	0.000828	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—prostate cancer	8.7e-05	0.000826	CcSEcCtD
Cyclizine—Reboxetine—CYP3A4—prostate cancer	8.69e-05	0.0333	CrCbGaD
Cyclizine—Tachycardia—Docetaxel—prostate cancer	8.68e-05	0.000824	CcSEcCtD
Cyclizine—Headache—Estradiol—prostate cancer	8.65e-05	0.000821	CcSEcCtD
Cyclizine—Benzatropine—CYP2C19—prostate cancer	8.64e-05	0.0331	CrCbGaD
Cyclizine—Skin disorder—Docetaxel—prostate cancer	8.64e-05	0.00082	CcSEcCtD
Cyclizine—Agitation—Prednisone—prostate cancer	8.63e-05	0.00082	CcSEcCtD
Cyclizine—Angioedema—Prednisone—prostate cancer	8.59e-05	0.000815	CcSEcCtD
Cyclizine—Urticaria—Etoposide—prostate cancer	8.5e-05	0.000807	CcSEcCtD
Cyclizine—Nervous system disorder—Capecitabine—prostate cancer	8.44e-05	0.000802	CcSEcCtD
Cyclizine—Hepatitis—Epirubicin—prostate cancer	8.44e-05	0.000801	CcSEcCtD
Cyclizine—Tachycardia—Capecitabine—prostate cancer	8.4e-05	0.000798	CcSEcCtD
Cyclizine—Skin disorder—Capecitabine—prostate cancer	8.36e-05	0.000794	CcSEcCtD
Cyclizine—Hypotension—Docetaxel—prostate cancer	8.31e-05	0.000789	CcSEcCtD
Cyclizine—Connective tissue disorder—Epirubicin—prostate cancer	8.3e-05	0.000788	CcSEcCtD
Cyclizine—Hepatobiliary disease—Doxorubicin—prostate cancer	8.23e-05	0.000781	CcSEcCtD
Cyclizine—Convulsion—Prednisone—prostate cancer	8.14e-05	0.000773	CcSEcCtD
Cyclizine—Agranulocytosis—Doxorubicin—prostate cancer	8.12e-05	0.000771	CcSEcCtD
Cyclizine—Hypertension—Prednisone—prostate cancer	8.11e-05	0.00077	CcSEcCtD
Cyclizine—Diphenhydramine—SLC22A1—prostate cancer	8.09e-05	0.031	CrCbGaD
Cyclizine—Headache—Mitoxantrone—prostate cancer	8.06e-05	0.000765	CcSEcCtD
Cyclizine—Hypotension—Capecitabine—prostate cancer	8.04e-05	0.000764	CcSEcCtD
Cyclizine—Insomnia—Docetaxel—prostate cancer	8.04e-05	0.000764	CcSEcCtD
Cyclizine—Paraesthesia—Docetaxel—prostate cancer	7.98e-05	0.000758	CcSEcCtD
Cyclizine—Somnolence—Docetaxel—prostate cancer	7.9e-05	0.00075	CcSEcCtD
Cyclizine—Eye disorder—Epirubicin—prostate cancer	7.89e-05	0.000749	CcSEcCtD
Cyclizine—Hypersensitivity—Etoposide—prostate cancer	7.88e-05	0.000748	CcSEcCtD
Cyclizine—Hepatitis—Doxorubicin—prostate cancer	7.81e-05	0.000742	CcSEcCtD
Cyclizine—Flunarizine—CYP1A1—prostate cancer	7.8e-05	0.0299	CrCbGaD
Cyclizine—Insomnia—Capecitabine—prostate cancer	7.79e-05	0.000739	CcSEcCtD
Cyclizine—Paraesthesia—Capecitabine—prostate cancer	7.73e-05	0.000734	CcSEcCtD
Cyclizine—Asthenia—Etoposide—prostate cancer	7.68e-05	0.000729	CcSEcCtD
Cyclizine—Connective tissue disorder—Doxorubicin—prostate cancer	7.68e-05	0.000729	CcSEcCtD
Cyclizine—Anaphylactic shock—Prednisone—prostate cancer	7.67e-05	0.000728	CcSEcCtD
Cyclizine—Constipation—Docetaxel—prostate cancer	7.6e-05	0.000722	CcSEcCtD
Cyclizine—Pain—Docetaxel—prostate cancer	7.6e-05	0.000722	CcSEcCtD
Cyclizine—Chills—Epirubicin—prostate cancer	7.57e-05	0.000719	CcSEcCtD
Cyclizine—Pruritus—Etoposide—prostate cancer	7.57e-05	0.000719	CcSEcCtD
Cyclizine—Nervous system disorder—Prednisone—prostate cancer	7.52e-05	0.000714	CcSEcCtD
Cyclizine—Tachycardia—Prednisone—prostate cancer	7.48e-05	0.000711	CcSEcCtD
Cyclizine—Skin disorder—Prednisone—prostate cancer	7.45e-05	0.000707	CcSEcCtD
Cyclizine—Mental disorder—Epirubicin—prostate cancer	7.4e-05	0.000702	CcSEcCtD
Cyclizine—Pain—Capecitabine—prostate cancer	7.36e-05	0.000699	CcSEcCtD
Cyclizine—Constipation—Capecitabine—prostate cancer	7.36e-05	0.000699	CcSEcCtD
Cyclizine—Erythema—Epirubicin—prostate cancer	7.35e-05	0.000698	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—prostate cancer	7.3e-05	0.000693	CcSEcCtD
Cyclizine—Tension—Epirubicin—prostate cancer	7.21e-05	0.000685	CcSEcCtD
Cyclizine—Nervousness—Epirubicin—prostate cancer	7.14e-05	0.000678	CcSEcCtD
Cyclizine—Dizziness—Etoposide—prostate cancer	7.08e-05	0.000672	CcSEcCtD
Cyclizine—Muscle spasms—Epirubicin—prostate cancer	7.07e-05	0.000671	CcSEcCtD
Cyclizine—Chills—Doxorubicin—prostate cancer	7.01e-05	0.000665	CcSEcCtD
Cyclizine—Insomnia—Prednisone—prostate cancer	6.94e-05	0.000658	CcSEcCtD
Cyclizine—Vision blurred—Epirubicin—prostate cancer	6.93e-05	0.000658	CcSEcCtD
Cyclizine—Paraesthesia—Prednisone—prostate cancer	6.89e-05	0.000654	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—prostate cancer	6.84e-05	0.00065	CcSEcCtD
Cyclizine—Urticaria—Capecitabine—prostate cancer	6.84e-05	0.000649	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—prostate cancer	6.8e-05	0.000646	CcSEcCtD
Cyclizine—Agitation—Epirubicin—prostate cancer	6.75e-05	0.000641	CcSEcCtD
Cyclizine—Headache—Etoposide—prostate cancer	6.7e-05	0.000636	CcSEcCtD
Cyclizine—Tension—Doxorubicin—prostate cancer	6.67e-05	0.000633	CcSEcCtD
Cyclizine—Clozapine—CYP1B1—prostate cancer	6.62e-05	0.0253	CrCbGaD
Cyclizine—Nervousness—Doxorubicin—prostate cancer	6.6e-05	0.000627	CcSEcCtD
Cyclizine—Constipation—Prednisone—prostate cancer	6.56e-05	0.000623	CcSEcCtD
Cyclizine—Hypersensitivity—Docetaxel—prostate cancer	6.55e-05	0.000622	CcSEcCtD
Cyclizine—Muscle spasms—Doxorubicin—prostate cancer	6.54e-05	0.000621	CcSEcCtD
Cyclizine—Vision blurred—Doxorubicin—prostate cancer	6.41e-05	0.000608	CcSEcCtD
Cyclizine—Modafinil—CYP2C19—prostate cancer	6.4e-05	0.0245	CrCbGaD
Cyclizine—Asthenia—Docetaxel—prostate cancer	6.38e-05	0.000606	CcSEcCtD
Cyclizine—Convulsion—Epirubicin—prostate cancer	6.37e-05	0.000604	CcSEcCtD
Cyclizine—Hypertension—Epirubicin—prostate cancer	6.34e-05	0.000602	CcSEcCtD
Cyclizine—Hypersensitivity—Capecitabine—prostate cancer	6.34e-05	0.000602	CcSEcCtD
Cyclizine—Pruritus—Docetaxel—prostate cancer	6.29e-05	0.000597	CcSEcCtD
Cyclizine—Agitation—Doxorubicin—prostate cancer	6.25e-05	0.000593	CcSEcCtD
Cyclizine—Bifonazole—CYP3A4—prostate cancer	6.19e-05	0.0237	CrCbGaD
Cyclizine—Asthenia—Capecitabine—prostate cancer	6.18e-05	0.000586	CcSEcCtD
Cyclizine—Cinnarizine—CYP1A1—prostate cancer	6.16e-05	0.0236	CrCbGaD
Cyclizine—Phenoxybenzamine—ADRB2—prostate cancer	6.16e-05	0.0236	CrCbGaD
Cyclizine—Urticaria—Prednisone—prostate cancer	6.09e-05	0.000578	CcSEcCtD
Cyclizine—Pruritus—Capecitabine—prostate cancer	6.09e-05	0.000578	CcSEcCtD
Cyclizine—Anaphylactic shock—Epirubicin—prostate cancer	6e-05	0.000569	CcSEcCtD
Cyclizine—Convulsion—Doxorubicin—prostate cancer	5.89e-05	0.000559	CcSEcCtD
Cyclizine—Nervous system disorder—Epirubicin—prostate cancer	5.88e-05	0.000558	CcSEcCtD
Cyclizine—Dizziness—Docetaxel—prostate cancer	5.88e-05	0.000558	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—prostate cancer	5.87e-05	0.000557	CcSEcCtD
Cyclizine—Tachycardia—Epirubicin—prostate cancer	5.85e-05	0.000556	CcSEcCtD
Cyclizine—Skin disorder—Epirubicin—prostate cancer	5.83e-05	0.000553	CcSEcCtD
Cyclizine—Dizziness—Capecitabine—prostate cancer	5.69e-05	0.00054	CcSEcCtD
Cyclizine—Hypersensitivity—Prednisone—prostate cancer	5.65e-05	0.000536	CcSEcCtD
Cyclizine—Hypotension—Epirubicin—prostate cancer	5.6e-05	0.000532	CcSEcCtD
Cyclizine—Phenprocoumon—CYP3A4—prostate cancer	5.6e-05	0.0214	CrCbGaD
Cyclizine—Headache—Docetaxel—prostate cancer	5.57e-05	0.000529	CcSEcCtD
Cyclizine—Anaphylactic shock—Doxorubicin—prostate cancer	5.55e-05	0.000527	CcSEcCtD
Cyclizine—Asthenia—Prednisone—prostate cancer	5.5e-05	0.000522	CcSEcCtD
Cyclizine—Atomoxetine—CYP2C19—prostate cancer	5.5e-05	0.0211	CrCbGaD
Cyclizine—Nervous system disorder—Doxorubicin—prostate cancer	5.44e-05	0.000517	CcSEcCtD
Cyclizine—Pruritus—Prednisone—prostate cancer	5.43e-05	0.000515	CcSEcCtD
Cyclizine—Insomnia—Epirubicin—prostate cancer	5.42e-05	0.000515	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—prostate cancer	5.42e-05	0.000514	CcSEcCtD
Cyclizine—Headache—Capecitabine—prostate cancer	5.39e-05	0.000512	CcSEcCtD
Cyclizine—Skin disorder—Doxorubicin—prostate cancer	5.39e-05	0.000512	CcSEcCtD
Cyclizine—Paraesthesia—Epirubicin—prostate cancer	5.39e-05	0.000511	CcSEcCtD
Cyclizine—Somnolence—Epirubicin—prostate cancer	5.33e-05	0.000506	CcSEcCtD
Cyclizine—Hypotension—Doxorubicin—prostate cancer	5.19e-05	0.000492	CcSEcCtD
Cyclizine—Constipation—Epirubicin—prostate cancer	5.13e-05	0.000487	CcSEcCtD
Cyclizine—Pain—Epirubicin—prostate cancer	5.13e-05	0.000487	CcSEcCtD
Cyclizine—Clozapine—CYP2A6—prostate cancer	5.1e-05	0.0195	CrCbGaD
Cyclizine—Dizziness—Prednisone—prostate cancer	5.07e-05	0.000481	CcSEcCtD
Cyclizine—Insomnia—Doxorubicin—prostate cancer	5.02e-05	0.000477	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—prostate cancer	4.98e-05	0.000473	CcSEcCtD
Cyclizine—Somnolence—Doxorubicin—prostate cancer	4.93e-05	0.000468	CcSEcCtD
Cyclizine—Headache—Prednisone—prostate cancer	4.8e-05	0.000456	CcSEcCtD
Cyclizine—Urticaria—Epirubicin—prostate cancer	4.76e-05	0.000452	CcSEcCtD
Cyclizine—Pain—Doxorubicin—prostate cancer	4.75e-05	0.000451	CcSEcCtD
Cyclizine—Constipation—Doxorubicin—prostate cancer	4.75e-05	0.000451	CcSEcCtD
Cyclizine—Diphenhydramine—CYP2C19—prostate cancer	4.44e-05	0.017	CrCbGaD
Cyclizine—Hypersensitivity—Epirubicin—prostate cancer	4.42e-05	0.00042	CcSEcCtD
Cyclizine—Urticaria—Doxorubicin—prostate cancer	4.41e-05	0.000419	CcSEcCtD
Cyclizine—Asthenia—Epirubicin—prostate cancer	4.3e-05	0.000409	CcSEcCtD
Cyclizine—Orphenadrine—CYP2E1—prostate cancer	4.24e-05	0.0162	CrCbGaD
Cyclizine—Pruritus—Epirubicin—prostate cancer	4.24e-05	0.000403	CcSEcCtD
Cyclizine—Hypersensitivity—Doxorubicin—prostate cancer	4.09e-05	0.000388	CcSEcCtD
Cyclizine—Modafinil—CYP3A4—prostate cancer	4.07e-05	0.0156	CrCbGaD
Cyclizine—Asthenia—Doxorubicin—prostate cancer	3.98e-05	0.000378	CcSEcCtD
Cyclizine—Fentanyl—CYP3A4—prostate cancer	3.98e-05	0.0152	CrCbGaD
Cyclizine—Dizziness—Epirubicin—prostate cancer	3.97e-05	0.000377	CcSEcCtD
Cyclizine—Pruritus—Doxorubicin—prostate cancer	3.93e-05	0.000373	CcSEcCtD
Cyclizine—Prochlorperazine—CYP3A4—prostate cancer	3.78e-05	0.0145	CrCbGaD
Cyclizine—Headache—Epirubicin—prostate cancer	3.76e-05	0.000357	CcSEcCtD
Cyclizine—Dizziness—Doxorubicin—prostate cancer	3.67e-05	0.000348	CcSEcCtD
Cyclizine—Clozapine—CYP2E1—prostate cancer	3.62e-05	0.0139	CrCbGaD
Cyclizine—Clozapine—CYP2C19—prostate cancer	3.59e-05	0.0137	CrCbGaD
Cyclizine—Clozapine—CYP1A1—prostate cancer	3.57e-05	0.0137	CrCbGaD
Cyclizine—Benzphetamine—CYP3A4—prostate cancer	3.53e-05	0.0135	CrCbGaD
Cyclizine—Atomoxetine—CYP3A4—prostate cancer	3.5e-05	0.0134	CrCbGaD
Cyclizine—Headache—Doxorubicin—prostate cancer	3.48e-05	0.00033	CcSEcCtD
Cyclizine—Mianserin—CYP3A4—prostate cancer	3.42e-05	0.0131	CrCbGaD
Cyclizine—Phenoxybenzamine—CYP3A4—prostate cancer	3.37e-05	0.0129	CrCbGaD
Cyclizine—Orphenadrine—CYP3A4—prostate cancer	2.67e-05	0.0102	CrCbGaD
Cyclizine—Clozapine—CYP3A4—prostate cancer	2.28e-05	0.00873	CrCbGaD
Cyclizine—CYP2C9—Metabolism—MBTPS1—prostate cancer	1.23e-05	0.000112	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SULT2B1—prostate cancer	1.23e-05	0.000112	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAGLU—prostate cancer	1.23e-05	0.000112	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AOX1—prostate cancer	1.23e-05	0.000112	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ANXA1—prostate cancer	1.2e-05	0.00011	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	1.2e-05	0.00011	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RALBP1—prostate cancer	1.19e-05	0.000109	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MC2R—prostate cancer	1.19e-05	0.000109	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AMACR—prostate cancer	1.16e-05	0.000106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP3A43—prostate cancer	1.16e-05	0.000106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—DEGS1—prostate cancer	1.16e-05	0.000106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAT1—prostate cancer	1.16e-05	0.000106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SRD5A2—prostate cancer	1.16e-05	0.000106	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PTHLH—prostate cancer	1.16e-05	0.000106	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	1.14e-05	0.000105	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	1.14e-05	0.000104	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PRKACB—prostate cancer	1.13e-05	0.000104	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CALCA—prostate cancer	1.12e-05	0.000103	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HSD17B1—prostate cancer	1.11e-05	0.000101	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	1.11e-05	0.000101	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PPP3CA—prostate cancer	1.11e-05	0.000101	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CXCL12—prostate cancer	1.1e-05	0.0001	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ANXA1—prostate cancer	1.09e-05	9.97e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	1.07e-05	9.75e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PENK—prostate cancer	1.06e-05	9.72e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	1.06e-05	9.7e-05	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	1.06e-05	9.67e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	1.05e-05	9.6e-05	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	1.04e-05	9.55e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CALCA—prostate cancer	1.02e-05	9.34e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GHR—prostate cancer	1.01e-05	9.28e-05	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—PIK3CA—prostate cancer	1.01e-05	9.26e-05	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PIK3CA—prostate cancer	1.01e-05	9.25e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PRKCQ—prostate cancer	1e-05	9.17e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	1e-05	9.15e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CXCL12—prostate cancer	9.97e-06	9.12e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HPGD—prostate cancer	9.88e-06	9.04e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—B4GALT4—prostate cancer	9.88e-06	9.04e-05	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	9.86e-06	9.02e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NRP1—prostate cancer	9.72e-06	8.89e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ADRB2—prostate cancer	9.42e-06	8.62e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TNFRSF21—prostate cancer	9.29e-06	8.5e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—VAV3—prostate cancer	9.19e-06	8.4e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PRKCQ—prostate cancer	9.1e-06	8.32e-05	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	9.06e-06	8.29e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VIP—prostate cancer	9.04e-06	8.27e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GNRH1—prostate cancer	9.04e-06	8.27e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP7B1—prostate cancer	9.04e-06	8.27e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTAP—prostate cancer	9.04e-06	8.27e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ITPR1—prostate cancer	8.91e-06	8.15e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	8.83e-06	8.08e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SRD5A1—prostate cancer	8.81e-06	8.06e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SULT1E1—prostate cancer	8.81e-06	8.06e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LPAR1—prostate cancer	8.75e-06	8.01e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GRP—prostate cancer	8.75e-06	8.01e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PLCB2—prostate cancer	8.67e-06	7.93e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LRP2—prostate cancer	8.67e-06	7.93e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ADRB2—prostate cancer	8.55e-06	7.83e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	8.55e-06	7.82e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CX3CL1—prostate cancer	8.5e-06	7.77e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—P4HB—prostate cancer	8.5e-06	7.77e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	8.43e-06	7.71e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HSD17B3—prostate cancer	8.4e-06	7.68e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ACSL4—prostate cancer	8.4e-06	7.68e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—VAV3—prostate cancer	8.34e-06	7.63e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIST1H2BG—prostate cancer	8.34e-06	7.63e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	8.3e-06	7.6e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GRB7—prostate cancer	8.27e-06	7.56e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PDE4D—prostate cancer	8.27e-06	7.56e-05	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—AKT1—prostate cancer	8.26e-06	7.56e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ITPR1—prostate cancer	8.09e-06	7.4e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIST1H4H—prostate cancer	8.06e-06	7.37e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PHGDH—prostate cancer	8.05e-06	7.37e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—UMPS—prostate cancer	8.05e-06	7.37e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ARG2—prostate cancer	8.05e-06	7.37e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CXCL8—prostate cancer	8.05e-06	7.36e-05	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	8.02e-06	7.34e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	8.01e-06	7.33e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LDHB—prostate cancer	7.9e-06	7.23e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GNG5—prostate cancer	7.86e-06	7.19e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP3A5—prostate cancer	7.75e-06	7.09e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PDHA1—prostate cancer	7.49e-06	6.85e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA3—prostate cancer	7.49e-06	6.85e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—UCP3—prostate cancer	7.49e-06	6.85e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TCN2—prostate cancer	7.49e-06	6.85e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HSD3B1—prostate cancer	7.14e-06	6.53e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC22A3—prostate cancer	7.14e-06	6.53e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	6.93e-06	6.34e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PTHLH—prostate cancer	6.85e-06	6.27e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFBR1—prostate cancer	6.85e-06	6.27e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA4—prostate cancer	6.85e-06	6.26e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TBXAS1—prostate cancer	6.85e-06	6.26e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKR1C3—prostate cancer	6.74e-06	6.16e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PRKACB—prostate cancer	6.7e-06	6.13e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	6.69e-06	6.12e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA2—prostate cancer	6.67e-06	6.1e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SULT1A1—prostate cancer	6.59e-06	6.03e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCG5—prostate cancer	6.59e-06	6.03e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PPP3CA—prostate cancer	6.53e-06	5.98e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—THBS1—prostate cancer	6.53e-06	5.98e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ANXA1—prostate cancer	6.44e-06	5.89e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA1—prostate cancer	6.44e-06	5.89e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAT2—prostate cancer	6.37e-06	5.82e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTO1—prostate cancer	6.37e-06	5.82e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HSD3B2—prostate cancer	6.37e-06	5.82e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PRKCZ—prostate cancer	6.32e-06	5.78e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CG—prostate cancer	6.18e-06	5.65e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	6.12e-06	5.6e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PARP1—prostate cancer	6.11e-06	5.58e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGFR4—prostate cancer	6.11e-06	5.58e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PLCB2—prostate cancer	6.1e-06	5.58e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2C18—prostate cancer	6.1e-06	5.58e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LRP2—prostate cancer	6.1e-06	5.58e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CALCA—prostate cancer	6.03e-06	5.52e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—P4HB—prostate cancer	5.99e-06	5.48e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL12—prostate cancer	5.89e-06	5.39e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC22A1—prostate cancer	5.82e-06	5.33e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	5.76e-06	5.27e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SULT2A1—prostate cancer	5.67e-06	5.19e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CG—prostate cancer	5.61e-06	5.13e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MED12—prostate cancer	5.58e-06	5.11e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CASP9—prostate cancer	5.55e-06	5.07e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GNG5—prostate cancer	5.54e-06	5.07e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CD—prostate cancer	5.43e-06	4.97e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NGFR—prostate cancer	5.38e-06	4.92e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PRKCQ—prostate cancer	5.38e-06	4.92e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOA3—prostate cancer	5.34e-06	4.88e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAP3K7—prostate cancer	5.31e-06	4.86e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	5.24e-06	4.8e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGF10—prostate cancer	5.11e-06	4.67e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HPGDS—prostate cancer	5.09e-06	4.66e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2C19—prostate cancer	5.06e-06	4.63e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ADRB2—prostate cancer	5.05e-06	4.62e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—JAK2—prostate cancer	4.99e-06	4.56e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MAP2K1—prostate cancer	4.97e-06	4.54e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ACHE—prostate cancer	4.94e-06	4.52e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTT1—prostate cancer	4.94e-06	4.52e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CD—prostate cancer	4.93e-06	4.51e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VAV3—prostate cancer	4.93e-06	4.51e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2A6—prostate cancer	4.88e-06	4.46e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.86e-06	4.45e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFBR2—prostate cancer	4.86e-06	4.44e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ITPR1—prostate cancer	4.78e-06	4.37e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AKR1C3—prostate cancer	4.75e-06	4.34e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CB—prostate cancer	4.73e-06	4.33e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PRKACB—prostate cancer	4.72e-06	4.32e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP17A1—prostate cancer	4.67e-06	4.27e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.61e-06	4.22e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1R—prostate cancer	4.57e-06	4.18e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CXCL8—prostate cancer	4.55e-06	4.16e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—JAK2—prostate cancer	4.53e-06	4.14e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOA2—prostate cancer	4.45e-06	4.07e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LPL—prostate cancer	4.38e-06	4.01e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—IL2—prostate cancer	4.35e-06	3.98e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PDGFRB—prostate cancer	4.34e-06	3.97e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CB—prostate cancer	4.3e-06	3.93e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC5A5—prostate cancer	4.25e-06	3.89e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ITGB3—prostate cancer	4.23e-06	3.87e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.15e-06	3.8e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CXCL8—prostate cancer	4.13e-06	3.78e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB3—prostate cancer	4.1e-06	3.75e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NQO1—prostate cancer	4.1e-06	3.75e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGFR2—prostate cancer	4.1e-06	3.75e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TH—prostate cancer	4.04e-06	3.7e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.02e-06	3.67e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP3A4—prostate cancer	4e-06	3.66e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.98e-06	3.64e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL2—prostate cancer	3.95e-06	3.61e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TERT—prostate cancer	3.93e-06	3.6e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.93e-06	3.6e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GGT1—prostate cancer	3.81e-06	3.48e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIF1A—prostate cancer	3.76e-06	3.44e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOA1—prostate cancer	3.75e-06	3.43e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP19A1—prostate cancer	3.7e-06	3.38e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LEP—prostate cancer	3.67e-06	3.36e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CAV1—prostate cancer	3.64e-06	3.33e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KDR—prostate cancer	3.6e-06	3.29e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—RXRA—prostate cancer	3.57e-06	3.26e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ESR1—prostate cancer	3.51e-06	3.21e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.47e-06	3.18e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—COMT—prostate cancer	3.44e-06	3.14e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—BAD—prostate cancer	3.42e-06	3.13e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTP1—prostate cancer	3.42e-06	3.13e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ITPR1—prostate cancer	3.37e-06	3.08e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CG—prostate cancer	3.31e-06	3.03e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APC—prostate cancer	3.31e-06	3.03e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.31e-06	3.03e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGF—prostate cancer	3.28e-06	3e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IRS1—prostate cancer	3.28e-06	3e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TYMS—prostate cancer	3.18e-06	2.91e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GSK3B—prostate cancer	3.18e-06	2.91e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTM1—prostate cancer	3.14e-06	2.88e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—INS—prostate cancer	3.14e-06	2.87e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LPL—prostate cancer	3.09e-06	2.82e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CREBBP—prostate cancer	3.07e-06	2.81e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1—prostate cancer	3.03e-06	2.78e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EGFR—prostate cancer	3.02e-06	2.76e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.98e-06	2.73e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ERCC2—prostate cancer	2.96e-06	2.7e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	2.93e-06	2.68e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	2.91e-06	2.67e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	2.89e-06	2.64e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	2.88e-06	2.64e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—KRAS—prostate cancer	2.85e-06	2.61e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGF2—prostate cancer	2.79e-06	2.55e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTHFR—prostate cancer	2.78e-06	2.54e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOS3—prostate cancer	2.75e-06	2.52e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARA—prostate cancer	2.73e-06	2.49e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JAK2—prostate cancer	2.67e-06	2.45e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	2.62e-06	2.4e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MDM2—prostate cancer	2.61e-06	2.39e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB2—prostate cancer	2.57e-06	2.35e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CAV1—prostate cancer	2.56e-06	2.34e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	2.54e-06	2.32e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.45e-06	2.24e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL8—prostate cancer	2.44e-06	2.23e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	2.38e-06	2.18e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	2.36e-06	2.16e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CASP3—prostate cancer	2.34e-06	2.14e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.33e-06	2.14e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL2—prostate cancer	2.33e-06	2.13e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL6—prostate cancer	2.32e-06	2.12e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCND1—prostate cancer	2.27e-06	2.08e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	2.25e-06	2.06e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—INS—prostate cancer	2.21e-06	2.02e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP9—prostate cancer	2.21e-06	2.02e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	2.2e-06	2.01e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PTEN—prostate cancer	2.19e-06	2.01e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CREBBP—prostate cancer	2.16e-06	1.98e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKT1—prostate cancer	2.14e-06	1.96e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EP300—prostate cancer	2.09e-06	1.91e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.05e-06	1.88e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SRC—prostate cancer	2.04e-06	1.86e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VEGFA—prostate cancer	1.98e-06	1.81e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—STAT3—prostate cancer	1.96e-06	1.8e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NOS3—prostate cancer	1.94e-06	1.77e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MYC—prostate cancer	1.82e-06	1.67e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFB1—prostate cancer	1.82e-06	1.66e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.79e-06	1.64e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGFR—prostate cancer	1.78e-06	1.63e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—prostate cancer	1.77e-06	1.62e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KRAS—prostate cancer	1.69e-06	1.54e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	1.55e-06	1.42e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTEN—prostate cancer	1.55e-06	1.41e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—prostate cancer	1.5e-06	1.37e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—EP300—prostate cancer	1.47e-06	1.35e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL6—prostate cancer	1.37e-06	1.25e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKT1—prostate cancer	1.26e-06	1.16e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.09e-06	9.98e-06	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AKT1—prostate cancer	8.91e-07	8.15e-06	CbGpPWpGaD
